• One-year survival rate and mean survival time [ Designated as safety issue: No ]
• Objective response rate and local control [ Designated as safety issue: No ]
• Tolerability [ Designated as safety issue: Yes ]
• Safety profile, in terms of acute and delayed toxicity [ Designated as safety issue: Yes ]

• One-year survival rate and mean survival time
• Objective response rate and local control
• Tolerability
• Safety profile, in terms of acute and delayed toxicity

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as paclitaxel may make tumor cells more sensitive to radiation therapy. It is not yet known if combination chemotherapy followed by radiation therapy is more effective with or without paclitaxel in treating unresectable stage III non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy followed by radiation therapy with or without paclitaxel in treating patients who have unresectable stage III non-small cell lung cancer.

OBJECTIVES:

• Compare the overall survival rate of patients with unresectable stage III non-small cell lung cancer treated with paclitaxel and carboplatin or cisplatin followed by radiotherapy with or without concurrent paclitaxel.
• Compare the 1-year survival rate and mean survival time in patients treated with these regimens.
• Compare the objective response rate and local control in patients treated with these regimens.
• Compare the tolerability of these regimens in these patients.
• Compare the safety profile and toxicity of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

All patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes or cisplatin IV on day 1. Treatment repeats every 21 days for 2 courses. Patients then proceed to randomized treatment.

• Arm I: Patients receive paclitaxel IV over 1 hour on day 1 and radiotherapy on days 1-5 of each week for 6 weeks.
• Arm II: Patients receive radiotherapy 5 days a week for 7 weeks. Patients are followed every 3 months for 1 year, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this study within 3 years.

• Drug: carboplatin
• Drug: chemotherapy
• Drug: cisplatin
• Drug: paclitaxel
• Radiation: radiation therapy

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC)

  • Locoregionally advanced unresectable disease
  • Previously untreated
• Measurable disease
• No involvement of supraclavicular lymph nodes
• No cytologically positive pleural or pericardial effusion
• No invasion to the wall of the esophagus or the cardiac ventricle
• No bone marrow involvement
• No distant metastases

PATIENT CHARACTERISTICS:

Age:

• 18 to 70

Performance status:

• WHO 0-1

Life expectancy:

• At least 12 weeks

Hematopoietic:

• WBC greater than 4,000/mm^3
• Absolute neutrophil count greater than 2,000/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin greater than 10 g/dL

Hepatic:

• Bilirubin less than upper limit of normal (ULN)
• AST and ALT less than 2.5 times ULN
• Alkaline phosphatase less than 5 times ULN
• No hepatic abnormalities

Renal:

• Creatinine less than ULN

Cardiovascular:

• No myocardial infarction within the past 6 months
• No cardiac insufficiency
• No uncontrolled arrhythmia

Pulmonary:

• FEV1 greater than 1 L
• DLCO at least 30% predicted
• No pneumonia
• No other non-disease-related pulmonary complications

Other:

• No more than 10% of total weight loss over the past 6 months
• No other disease that would preclude study
• No peripheral neuropathy grade 3 or greater
• No other prior or concurrent malignancy except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix
• No familial, geographic, or psychological condition that would preclude study
• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior immunotherapy
• No concurrent immunotherapy

Chemotherapy:

• No prior systemic chemotherapy

Endocrine therapy:

• No concurrent endocrine therapy

Radiotherapy:

• No prior radiotherapy for NSCLC

Surgery:

• See Disease Characteristics
• No prior complete resection of tumor
• Prior radical surgical resection allowed if local recurrence of disease
• No concurrent major surgery

Other:

• No other concurrent anticancer therapy or investigational agents